“Using immunotherapy alongside chemotherapy has proved promising in a recent phase 3, multicenter, clinical trial of patients with non-small cell lung cancer that has spread. Following the publication of the trial results, the Food and Drug Administration (FDA) has approved AstraZeneca’s drugs Imfinzi (durvalumab) and Imjudo (tremelimumab) alongside chemotherapy already approved in the U.S. for patients with metastatic non-small cell lung cancer.”
Ultrafine particles can change defense against lung cancer
“While it may seem common knowledge that smoking is bad for your lungs, if and how ultrafine particles present in cigarette smoke impact the development and progression of lung cancer remains unclear. Researchers at Baylor College of Medicine sought to find how airborne ultrafine particles in smoke can change a host’s defense against lung cancer.”
Tumor matrix profiles determine the risk and prognosis of a common type of lung cancer
“Scientists at the Garvan Institute of Medical Research have identified molecular profiles of the surrounding matrix of a common type of lung cancer that might indicate which patients are likely to develop aggressive tumors.”
FDA rejects Spectrum’s lung cancer drug poziotinib
“Spectrum is expected to make an announcement later today, but the CRL has been widely anticipated, given that the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9 to 4 against approval of poziotinib in September, saying that the benefits of poziotinib do not outweigh its risks. Spectrum filed for accelerated approval of poziotinib as a second-line treatment for patients with HER2 exon 20 insertion-mutated, non-small cell lung cancer (NSCLC), but the FDA was unconvinced by the phase 2 data presented in support of the drug.”
Tepotinib and Gefitinib Show Long OS in EGFR+ NSCLC With MET Amplification
The combination of tepotinib (Tepmetko) and gefitinib (Iressa) demonstrated an improvement in both progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) who developed MET-driven resistance to prior EGFR tyrosine kinase inhibitors (TKIs), according to findings from the final analysis of the phase 2 INSIGHT trial (NCT01982955).”
Impact of Loneliness on Functioning in Lung Cancer Patients
“Lung cancer is the leading cause of cancer death and carries a greater degree of stigma. Lung cancer stigma contributes to social isolation and increases loneliness, which has an impact on quality of life, increases depressive symptoms and hence affects all aspects of functioning. Functioning is assessed in five dimensions (physical, psychological, cognitive, social and life roles). The aim of the study was to assess the impact of loneliness on the functioning, nutritional status and quality of life of patients with lung cancer.”
Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
“SHANGHAI and SUZHOU, China, Nov. 27, 2022 /PRNewswire/ — Lyvgen Biopharma, a leading innovative global biotech company dedicated to discovering, developing and commercializing first-in-class and best-in-class biotherapeutics for cancer, announced today an open label, phase 2, multicenter, randomized trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC).”
